Quince Therapeutics, Inc.
QNCXNASDAQHealthcare● Active
$1.00
+$0.00(+0.11%)
Market Cap$5574275
P/E Ratio—
52W High$45.5
52W Low$0.79
Quince Therapeutics, Inc. (QNCX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
QNCX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.59
Est. -$1.30 · +54.6%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
QNCX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.60 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 11, 2026 | -$1.30 | -$0.59 | +54.6% | — | — | — |
| ▼ Q2 FY2026 | Apr 10, 2026 | -$0.18 | -$4.30 | -2292.9% | — | — | — |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.20 | -$0.25 | -25.0% | — | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.28 | -$0.34 | -21.4% | — | — | — |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.24 | -$0.34 | -41.7% | — | — | — |
| ▼ Q1 FY2025 | Mar 24, 2025 | -$0.19 | -$0.28 | -47.4% | — | — | — |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.17 | -$0.13 | +25.0% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.60
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
-$0.59
EPS Est.
-$1.30
EPS Surpr.
+54.6%
Revenue
—
Q2 FY2026
Apr 10, 2026Miss
EPS Actual
-$4.30
EPS Est.
-$0.18
EPS Surpr.
-2292.9%
Revenue
—
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$0.25
EPS Est.
-$0.20
EPS Surpr.
-25.0%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.34
EPS Est.
-$0.28
EPS Surpr.
-21.4%
Revenue
—
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$0.34
EPS Est.
-$0.24
EPS Surpr.
-41.7%
Revenue
—
Q1 FY2025
Mar 24, 2025Miss
EPS Actual
-$0.28
EPS Est.
-$0.19
EPS Surpr.
-47.4%
Revenue
—
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.13
EPS Est.
-$0.17
EPS Surpr.
+25.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.94 | $0.94 | $0.94 | 1 |
| Q3 FY2028 | $0.92 | $0.92 | $0.92 | 1 |
| Q2 FY2028 | $0.94 | $0.94 | $0.94 | 1 |
| Q1 FY2028 | $0.89 | $0.89 | $0.89 | 1 |
| Q4 FY2027 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Q3 FY2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +54.6% | $1.28 | $1.24 | -3.13% |
| ▼ Q2 FY2026 | Apr 10, 2026 | -2292.9% | $1.24 | $1.36 | +9.68% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -25.0% | $17.90 | $17.10 | -4.47% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -21.4% | $16.50 | $16.00 | -3.03% |
| ▼ Q2 FY2025 | May 13, 2025 | -41.7% | $10.30 | $9.50 | -7.77% |
| ▼ Q1 FY2025 | Mar 24, 2025 | -47.4% | $13.80 | $14.00 | +1.45% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +25.0% | $16.80 | $15.90 | -5.36% |
| — Q3 FY2024 | Aug 13, 2024 | — | $6.90 | $5.76 | -16.52% |
Q2 FY2026-3.13%
Report Date
May 11, 2026
EPS Beat/Miss
+54.6%
Price Before
$1.28
Price After
$1.24
Q2 FY2026+9.68%
Report Date
Apr 10, 2026
EPS Beat/Miss
-2292.9%
Price Before
$1.24
Price After
$1.36
Q4 FY2025-4.47%
Report Date
Nov 12, 2025
EPS Beat/Miss
-25.0%
Price Before
$17.90
Price After
$17.10
Q3 FY2025-3.03%
Report Date
Aug 11, 2025
EPS Beat/Miss
-21.4%
Price Before
$16.50
Price After
$16.00
Q2 FY2025-7.77%
Report Date
May 13, 2025
EPS Beat/Miss
-41.7%
Price Before
$10.30
Price After
$9.50
Q1 FY2025+1.45%
Report Date
Mar 24, 2025
EPS Beat/Miss
-47.4%
Price Before
$13.80
Price After
$14.00
Q4 FY2024-5.36%
Report Date
Nov 13, 2024
EPS Beat/Miss
+25.0%
Price Before
$16.80
Price After
$15.90
Q3 FY2024-16.52%
Report Date
Aug 13, 2024
EPS Beat/Miss
—
Price Before
$6.90
Price After
$5.76
Avg Beat Reaction-4.25%
Avg Miss Reaction-0.83%
Beat Rate2 / 8 quarters
Largest Move-16.52% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: QNCX ends December
Quince Therapeutics, Inc. (QNCX) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.59 — beating the analyst consensus of $-1.30 by +54.6%. The next QNCX earnings date is expected around September 1, 2026.
Each quarter, investors track QNCX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. QNCX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
QNCX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
QNCX earnings · 5 questionsQuince Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. QNCX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; QNCX historically reports after market close (AMC).
QNCX earnings datewhen is QNCX earningsQNCX next earnings datewhen does QNCX report earningsQNCX earnings calendar
▸ Source: FMP · Quince Therapeutics, Inc. SEC filings · US GAAP · Quince Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026